Form 4 for MIRM Mirum Pharmaceuticals, Inc.
Accepted 2026-08-12 17:14:43 ET · period of report 2026-08-11 · accession 0001197350-26-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-08-12 17:14 | 2026-08-11 | MIRM | BJERKHOLT ERIC | CFO | S - Sale | $99.90 | -6,001 | 36.4K | -14% | -$599.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-11 | S | D | 6,001 | $99.90 | 36,355 | D | — | — | (F1) Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 9, 2026. (F2) . The weighted average sale price for the transaction reported was $99.901633, and the range of prices were between $99.90 and $99.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. (F3) Includes 175 shares of common stock that were acquired by the Reporting Person on May 10, 2026, pursuant to the Issuer's Employee Stock Purchase Plan. |